Formosa Pharmaceuticals News
Formosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI – August 16, 2023 – Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TWO) announced today that the company has entered into a licensing agreement with Eyenovia, Inc. …
Formosa Pharmaceuticals Announce FDA Acceptance of NDA Filing for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
July 5th, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) announce the United States Food & Drug Administration (US FDA) acceptance of its New Drug …
Formosa Pharmaceuticals and AimMax Therapeutics Announce the NDA Submission to the US FDA for APP13007 for the Treatment of Post-Operative Inflammation and Pain following Ocular Surgery
May 5th, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) and AimMax Therapeutics, Inc. (United States) announce the submission of a New Drug Application to …
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia
February 15th, 2023 The collaboration will combine Formosa’s proprietary APNT™ nanoparticle formulation platform with Eyenovia’s Optejet® dispensing technology for the development of new ophthalmic therapies …
Formosa Pharmaceuticals Announce a Summary of Integrated Clinical Results for APP13007 for the Treatment of Inflammation and Pain after Cataract Surgery
January 31st, 2023 TAIPEI, Taiwan – Formosa Pharmaceuticals, Inc. (6838.TWO) report a summary of integrated clinical results for APP13007, a novel ophthalmic nanosuspension formulation of …
Formosa Pharmaceuticals, completes successful pre-NDA Meeting with the US FDA and plans for NDA submission of APP13007
November 8th, 2022 Taipei, Taiwan – Formosa Pharmaceuticals, Inc. (TWO.6838) and development partner, AimMax Therapeutics, Inc. (US), announced the completion of a pre-NDA meeting with …
